# Epicrispr Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epicrispr-biotechnologies

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.epicrispr.com
- Total disclosed funding: $166M
- Latest round: Grant (Oct 19, 2026)
- Investors on record: 11

## About

Founded in 2018 by Lei Stanley Qi and based in California, US, Epicrispr Biotechnologies, Inc. is a biotechnology company developing ultracompact therapies to modulate gene expression. As of January 2023, Amber Salzman serves as the CEO of the company. In August 2026, Epicrispr Biotechnologies, Inc. raised USD 90 million in series C funding co-led by Janus Henderson Investors and Octagon Capital Advisors, with participation from Angelini Ventures, Cormorant Asset Management, Duquesne Family Office, Fidelity Investments, Readout Capital, Sanofi Ventures. The company plans to utilize  2026 funding to advance clinical studies for its lead therapy, expand its treatment pipeline, and grow manufacturing operations.

The company provides a platform, called the Gene Expression Modulation System (GEMS), that combines a DNA-binding protein, a customised guide RNA, and any of a wide array of modulator proteins to create a new type of genetic medicine. GEMS therapies can modulate gene expression both in vivo and ex vivo and are mutation-agnostic.

The firm also holds a licence for the miniature DNA-binding protein called CasMINI, which is the dCas protein that can work in human cells. The company’s product pipeline includes EPI-321, facioscapulohumeral muscular dystrophy (FSHD), EPI-221, heterozygous familial hypercholesterolemia (HeFH), EPI-241, alpha-1 antitrypsin deficiency (A1AD), EPI-141, retinitis pigmentosa 4 (RP4), and EPI-111, retinitis pigmentosa 11 (RP11).

## Funding rounds

- Grant, Oct 19, 2026, $8M — California Institute for Regenerative Medicine
- Series C, Aug 11, 2026, $90M — Fidelity Investments, Sanofi Ventures, Cormorant Asset Management, Duquesne Family Office, Janus Henderson Investors, Octagon Capital Advisors, Angelini Ventures, Readout Capital
- Series B, Mar 26, 2025, $68M — Ally Bridge Group, Solve FSHD

## Investors

- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B
- Solve FSHD — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Duquesne Family Office — Series C
- Janus Henderson Investors — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series C
- Readout Capital (https://capitalatlas.ai/funds/readout-capital) — Series C
- California Institute for Regenerative Medicine — Grant